Analysis of Vaccine Reactions After COVID-19 Vaccine Booster Doses Among Pregnant and Lactating Individuals.
JAMA Netw Open
; 5(9): e2230495, 2022 09 01.
Article
in English
| MEDLINE | ID: covidwho-2013246
ABSTRACT
Importance COVID-19 vaccine boosters or third doses are recommended for adolescents and adults who completed their initial COVID-19 vaccine course more than 5 months prior. Minimal data are available on COVID-19 vaccine booster or third dose reactogenicity among pregnant and lactating individuals. Objective:
To describe the reactions to the booster or third dose of the COVID-19 vaccine and vaccine experiences among pregnant and lactating individuals. Design, Setting, andParticipants:
Beginning in October 2021, a follow-up Research Electronic Data Capture (REDCap) survey regarding a COVID-19 vaccine booster or third dose was sent to 17â¯504 participants in an ongoing online prospective cohort study on COVID-19 vaccines among pregnant and lactating individuals. A convenience sample of adults enrolled in the online prospective study who were pregnant, lactating, or neither pregnant nor lactating at the time of their booster or third dose was eligible for this follow-up survey; 17â¯014 (97.2%) completed the follow-up survey. Exposure Receipt of a booster or third dose of the COVID-19 vaccine. Main Outcomes andMeasures:
Self-reported vaccine reactions less than 24 hours after the dose.Results:
As of April 4, 2022, 17â¯014 eligible participants (mean [SD] age, 33.3 [3.5] years) responded to the booster or third dose survey; of these, 2009 (11.8%) were pregnant at the time of their booster or third dose, 10â¯279 (60.4%) were lactating, and 4726 (27.8%) were neither pregnant nor lactating. After a COVID-19 booster or third dose, most individuals (14â¯074 of 17â¯005 [82.8%]) reported a local reaction, and 11â¯542 of 17â¯005 (67.9%) reported at least 1 systemic symptom. Compared with individuals who were neither pregnant nor lactating, pregnant participants were more likely to report any local reaction to a COVID-19 booster or third dose (adjusted odds ratio [aOR], 1.2; 95% CI, 1.0-1.4; P = .01) but less likely to report any systemic reaction (aOR, 0.7; 95% CI, 0.6-0.8; P < .001). Most pregnant (1961 of 2009 [97.6%]) and lactating (9866 of 10â¯277 [96.0%]) individuals reported no obstetric or lactation concerns after vaccination. Conclusions and Relevance This study suggests that COVID-19 vaccine boosters or third doses were well tolerated among pregnant and lactating individuals. Data to evaluate tolerability of boosters or additional doses among pregnant and lactating individuals will be important as they are considered for these populations.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pregnancy Complications, Infectious
/
Vaccines
/
COVID-19 Vaccines
/
COVID-19
Type of study:
Cohort study
/
Experimental Studies
/
Observational study
/
Prognostic study
/
Qualitative research
Topics:
Vaccines
Limits:
Adolescent
/
Adult
/
Female
/
Humans
/
Pregnancy
Language:
English
Journal:
JAMA Netw Open
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS